Department of Clinical Immunology, Karol Marcinkowski University of Medical Sciences, Poznań, Poland.
Department of Infectious Diseases, Hepatology and Acquired Immunodeficiencies, Karol Marcinkowski University of Medical Sciences, Poznań, Poland.
Arch Immunol Ther Exp (Warsz). 2019 Jun;67(3):133-141. doi: 10.1007/s00005-019-00540-x. Epub 2019 Apr 11.
Pattern recognition receptors (PRRs) are members of innate immunity, playing pivotal role in several immunological reactions. They are known to act as a bridge between innate and adaptive immunity. They are expressed on several normal cell types but have been shown with increasing frequency on/in tumor cells. Significance of this phenomenon is largely unknown, but it has been shown by several authors that they, predominantly Toll-like receptors (TLRs), act in the interest of tumor, by promotion of its growth and spreading. Preparation of artificial of TLRs ligands (agonists) paved the way to use them as a therapeutic agents for cancer, so far in a limited scale. Agonists may be combined with conventional anti-cancer modalities with apparently promising results. PRRs recognizing nucleic acids such as RIG-1 like receptors (sensing RNA) and STING (sensing DNA) constitute a novel promising approach for cancer immunotherapy.
模式识别受体（PRRs）是先天免疫的成员，在几种免疫反应中发挥关键作用。它们被认为是先天免疫和适应性免疫之间的桥梁。它们在几种正常细胞类型上表达，但在肿瘤细胞上的表达频率越来越高。这种现象的意义在很大程度上是未知的，但有几位作者已经表明，它们主要是 Toll 样受体（TLRs），通过促进肿瘤的生长和扩散，为肿瘤的利益而行动。人工 TLRs 配体（激动剂）的制备为将其用作癌症的治疗剂铺平了道路，但到目前为止，规模有限。激动剂可以与传统的抗癌方式联合使用，结果显然很有前景。识别核酸的 PRRs，如 RIG-1 样受体（感应 RNA）和 STING（感应 DNA），为癌症免疫治疗提供了一种新的有前途的方法。
